Novel biomarkers of chronic lung allograft dysfunction: is there anything reliable?
Evidence level: narrative review; abstract-only
A review states that none of the many proposed CLAD biomarkers is universally accepted or implemented, with most progress for donor-derived cell-free DNA and donor-specific antibodies.
As of . Primary source: Publisher record via DOI.
Summary
The review states that radiological and physiological markers are gradually entering routine practice, and that studies of lavage, biopsy and serum have generated potential biomarkers of fibrogenesis, airway injury and inflammation, but none is universally accepted or implemented. Progress is noted for donor-derived cell-free DNA and donor-specific antibodies. The authors state that adequate biomarkers to predict CLAD, its phenotype or prognosis are needed and that a very limited number has reached routine clinical practice.
Details
- doi
- 10.1097/MOT.0000000000000944
- pmid
- 34939958
- authors
- Verleden SE, Verleden GM
- journal
- Current Opinion in Organ Transplantation
- year
- 2022
- volume
- 27
- issue
- 1
- pages
- 1-6
Sources and links
- Publisher record via DOI (primary)
- PubMed 34939958
Related
Links from this record
- discusses: Donor-derived cell-free DNA
- discusses: Autoantibodies
- discusses: HLA donor-specific antibody and non-HLA antibody testing
- authors affiliated with: KU Leuven BREATHE (Laboratory of Respiratory Diseases and Thoracic Surgery)
- coauthor: Geert Verleden
Linked from (derived)
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- full text and list of reviewed biomarkers (not read)
- funding and conflicts of interest
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.